更新于：2024-06-22
Terbutaline Sulfate
硫酸特布他林
更新于：2024-06-22
概要
基本信息
药物类型 小分子化药 |
别名 Terbutaline、Terbutaline sulfate (JP17/USP)、Terbutaline Sulfate and Sodium Chloride + [17] |
作用机制 β2-adrenergic receptor激动剂(β2-肾上腺素能受体激动剂) |
非在研适应症 |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C12H21NO7S |
InChIKeyMUPQZWGSBCWCAV-UHFFFAOYSA-N |
CAS号23031-32-5 |
关联
41
项与 硫酸特布他林 相关的临床试验A Prospective, Blinded, Cross-Over Trial of the Exposure-Response Relationship of Terbutaline Sulfate in Adults With Asthma
A Multicenter Randomized Trial of Second Line Treatment for Corticosteroid-Resistant or Relapsed Immune Thrombocytopenia: Combined Terbutaline and Danazol Versus Danazol Monotherapy
Hot Flashes and Neurovascular Function in Women
100 项与 硫酸特布他林 相关的临床结果
登录后查看更多信息
100 项与 硫酸特布他林 相关的转化医学
登录后查看更多信息
100 项与 硫酸特布他林 相关的专利（医药）
登录后查看更多信息
3,485
项与 硫酸特布他林 相关的文献（医药）2024-03-01Oncology and therapy
Long Term Remission of Capillary Leak Syndrome Associated with Monoclonal Gammopathy with Progression to Multiple Myeloma After Autologous Stem Cell Transplantation: a Case Report and Review of the Literature
Article
作者: González-Quijada, Santiago ; Hermida, Gerardo ; González-López, Tomás José ; Alvarez-Nuño, Rodolfo ; San Miguel-Izquierdo, Jesús
BACKGROUND:
Clarkson's disease is a very rare entity characterised by acute episodes of systemic oedema and severe hypotension associated with paraproteinaemia. Its classical treatment relies on methylxanthine combined with terbutaline. Although this prophylactic therapy reduces the mortality rate, relapses are frequent. Eighty percent of patients with Clarkson's disease present with monoclonal gammopathy of unknown significance (MGUS). The risk of progression to multiple myeloma is 1% per year.
CASE DESCRIPTION:
Here, we present a 49-year-old woman who suffered multiple such episodes requiring treatment in the intensive care unit. Treatment with terbutaline and theophylline was ineffective. She was diagnosed with multiple myeloma (MM) 8 years after the first of these acute episodes. Antimyeloma treatment with bortezomib and dexamethasone was started, followed by autologous haemopoietic transplantation, with no further acute episodes since then.
CONCLUSION:
Our case is, to our knowledge, unique because eradication of MM was followed by complete disappearance of acute episodes of capillary leakage. Our case report is also the first to support the use of bortezomib and dexamethasone in this setting. Furthermore, autologous peripheral blood progenitor cell transplantation consolidated the MM stringent complete remission achieving a very long progression-free survival (> 11 years) of both MM and Clarkson's disease.
2024-02-01International journal of impotence research
Conservative and medical treatments of non-sickle cell disease-related ischemic priapism: a systematic review by the EAU Sexual and Reproductive Health Panel
Review
作者: Hatzichristodoulou, Georgios ; Dimitropolous, Kostas ; Kalkanlı, Arif ; Cocci, Andrea ; Minhas, Suks ; Capogrosso, Paolo ; Milenkovic, Uros ; Tharakan, Tharu ; Carvalho, Joana ; Jones, Hugh T ; Kadioglu, Ates ; Verze, Paolo ; Serefoglu, Ege Can ; Martinez-Salamanca, Juan Ignacio ; Corona, Giovanni ; Modgil, Vaibhav ; Salonia, Andrea ; Gül, Murat ; Bettocchi, Carlo ; Russo, Giorgio Ivan ; Boeri, Luca
Conservative and medical treatments are considered the first step in ischemic priapism (IP) management, although there is no clear evidence regarding their efficacy. We conducted a systematic review on behalf of the EAU Guidelines panel on Sexual and Reproductive health to analyse the available evidence on the efficacy and safety of conservative and medical treatment for non-sickle cell disease-related IP. Databases searched for relevant literature investigating efficacy and safety of conservative measures and medical treatment for IP included Medline, EMBASE, Cochrane Libraries and clinicaltrial.gov published up to September 2021. Overall, 41 retrospective, 3 prospective single-arm studies and 3 randomized controlled trials met the inclusion criteria. Intracavernous injection with sympathomimetic (ICIs) agents were the most frequently utilized treatment with efficacy ranging from 0 to 100% of cases. The combination of ICIs with corporeal aspiration with or without irrigation with saline was successful in 70 to 100% of cases. Oral treatment with β2 receptor agonist (e.g., terbutaline) showed mild to moderate efficacy. Conservative methods including ice pack, exercise, cold enema and ejaculation depicted lower effectiveness in resolving priapism (1-55%). Longer time interval from the onset to the resolution of IP was associated with higher rate of erectile dysfunction at follow-up (30-70%), especially after 24 h.
2024-01-01Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies
Wide Institutional Variability in the Treatment of Pediatric Critical Asthma: A Multicenter Retrospective Study
Article
作者: Waldo, Briana ; Carroll, Christopher L ; Hogan, Alexander H ; Rogerson, Colin M ; White, Benjamin R ; Shein, Steven L
OBJECTIVES::
Children with status asthmaticus refractory to first-line therapies of systemic corticosteroids and inhaled beta-agonists often receive additional treatments. Because there are no national guidelines on the use of asthma therapies in the PICU, we sought to evaluate institutional variability in the use of adjunctive asthma treatments and associations with length of stay (LOS) and PICU use.
DESIGN::
Multicenter retrospective cohort study.
SETTING::
Administrative data from the Pediatric Health Information Systems (PHIS) database.
PATIENTS::
All inpatients 2–18 years old were admitted to a PHIS hospital between 2013 and 2021 with a diagnostic code for asthma.
INTERVENTIONS::
None.
MEASUREMENTS AND MAIN RESULTS::
This study included 213,506 inpatient encounters for asthma, of which 29,026 patient encounters included care in a PICU from 39 institutions. Among these PICU encounters, large variability was seen across institutions in both the number of adjunctive asthma therapies used per encounter (min: 0.6, median: 1.7, max: 2.5, p < 0.01) and types of adjunctive asthma therapies (aminophylline, ipratropium, magnesium, epinephrine, and terbutaline) used. The center-level median hospital LOS ranged from 1 (interquartile range [IQR]: 1, 3) to 4 (3, 6) days. Among all the 213,506 inpatient encounters for asthma, the range of asthma admissions that resulted in PICU admission varied between centers from 5.2% to 47.3%. The average number of adjunctive therapies used per institution was not significantly associated with hospital LOS (p = 0.81) nor the percentage of encounters with PICU admission (p = 0.47).
CONCLUSIONS::
Use of adjunctive therapies for status asthmaticus varies widely among large children’s hospitals and was not associated with hospital LOS or the percentage of encounters with PICU admission. Wide variance presents an opportunity for standardizing care with evidence-based guidelines to optimize outcomes and decrease adverse treatment effects and hospital costs.
100 项与 硫酸特布他林 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 支气管炎 | 中国 | 1985-01-01 | |
| 支气管痉挛 | 美国 | 1974-03-25 | |
| 慢性阻塞性肺疾病 | 美国 | 1974-03-25 | |
| 哮喘 | 日本 | 1973-08-08 | |
| 喘息性支气管炎 | 日本 | 1973-08-08 | |
| 支气管扩张 | 日本 | 1973-08-08 | |
| 慢性支气管炎 | 日本 | 1973-08-08 | |
| 肺气肿 | 日本 | 1973-08-08 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 家族性嗜酸性粒细胞增多症 | 临床3期 | 丹麦 | 2005-05-01 | |
| 家族性嗜酸性粒细胞增多症 | 临床3期 | 法国 | 2005-05-01 | |
| 家族性嗜酸性粒细胞增多症 | 临床3期 | 德国 | 2005-05-01 | |
| 家族性嗜酸性粒细胞增多症 | 临床3期 | 西班牙 | 2005-05-01 | |
| 家族性嗜酸性粒细胞增多症 | 临床3期 | 瑞典 | 2005-05-01 | |
| 家族性嗜酸性粒细胞增多症 | 临床3期 | 英国 | 2005-05-01 | |
| 运动诱发哮喘 | 临床2期 | 挪威 | 2009-09-01 | |
| 运动诱发哮喘 | 临床2期 | 瑞典 | 2009-09-01 | |
| 间歇性哮喘 | 临床2期 | 挪威 | 2009-09-01 | |
| 间歇性哮喘 | 临床2期 | 瑞典 | 2009-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 34 | (Spinal Anesthesia Immediately for ECV.) | 鹹齋淵醖構鑰廠餘願窪(顧願鑰壓鹽繭鏇顧襯齋) = 壓繭鏇艱糧壓築餘獵鹽 齋艱淵獵製餘廠淵蓋夢 (願簾醖糧壓繭構齋壓衊, 淵憲醖膚齋鹽衊衊網壓 ~ 鬱憲繭選窪鏇衊願艱窪) 更多 | - | 2020-10-09 | |
(Spinal Anesthesia if no Intervention Fails for ECV.) | 鹹齋淵醖構鑰廠餘願窪(顧願鑰壓鹽繭鏇顧襯齋) = 製築積顧築餘襯築膚簾 齋艱淵獵製餘廠淵蓋夢 (願簾醖糧壓繭構齋壓衊, 鑰簾積鏇膚範鏇衊繭網 ~ 壓艱構鑰襯鏇選製範願) 更多 | ||||||
临床2/3期 | - | 6 | (Intravenous Terbutaline) | 糧齋繭廠鬱鹹繭鑰積積(遞膚製鏇願鏇壓繭觸遞) = 壓簾鹽鏇觸築遞醖遞壓 顧範製夢壓鏇蓋選築憲 (願願顧網淵壓襯鏇蓋鏇, 顧顧鬱獵廠積衊餘衊鬱 ~ 壓遞鏇齋衊築積積簾餘) 更多 | - | 2017-06-14 | |
(Intravenous Nitroglycerine) | 糧齋繭廠鬱鹹繭鑰積積(遞膚製鏇願鏇壓繭觸遞) = 憲範鏇膚願鏇淵鏇網網 顧範製夢壓鏇蓋選築憲 (願願顧網淵壓襯鏇蓋鏇, 繭鑰憲繭範願淵襯鹽餘 ~ 淵廠壓網網鹽鑰獵齋鏇) 更多 | ||||||
临床3期 | 95 | (M3 1.5 mg) | 壓築醖遞膚淵鏇衊獵網(製簾選範窪獵壓獵醖窪) = 艱積鏇夢糧夢製獵繭餘 醖蓋鑰製廠醖壓壓餘壓 (鏇鑰艱衊蓋網艱膚積鹹, 簾顧選鬱夢網簾鹹膚衊 ~ 簾構衊鬱夢築窪壓齋鑰) 更多 | - | 2016-11-06 | ||
(M3 0.5 mg) | 壓築醖遞膚淵鏇衊獵網(製簾選範窪獵壓獵醖窪) = 鹽艱構顧鏇遞顧壓窪廠 醖蓋鑰製廠醖壓壓餘壓 (鏇鑰艱衊蓋網艱膚積鹹, 窪憲積獵鹽淵艱夢餘觸 ~ 醖膚範繭窪艱憲遞築夢) 更多 | ||||||
临床1期 | - | 34 | (Bricanyl Turbuhaler M3) | 鹹餘糧簾齋膚壓獵網鬱(醖蓋顧醖願願鏇餘選艱) = 膚簾廠壓夢簾鹽壓繭壓 憲餘觸鏇鬱壓簾醖觸範 (製醖遞遞鑰範壓製糧艱, 窪齋壓糧壓選範鹽淵顧 ~ 獵壓壓鏇鹹顧膚鏇製範) 更多 | - | 2016-08-02 | |
(Bricanyl Turbuhaler M2) | 鹹餘糧簾齋膚壓獵網鬱(醖蓋顧醖願願鏇餘選艱) = 顧蓋鹽醖夢鏇糧糧觸願 憲餘觸鏇鬱壓簾醖觸範 (製醖遞遞鑰範壓製糧艱, 網獵衊襯選窪願鹽範鏇 ~ 繭繭壓齋網構齋獵艱憲) 更多 | ||||||
N/A | - | 10 | 艱鏇築鬱糧淵艱夢鑰鹽(範網繭簾醖窪糧齋鑰膚) = 鹽網願夢壓構糧餘鑰糧 膚鏇餘糧構鏇範鏇構構 (鹹顧簾願獵廠鑰鹽築鏇 ) 更多 | 积极 | 2013-09-01 | ||
Placebo | 艱鏇築鬱糧淵艱夢鑰鹽(範網繭簾醖窪糧齋鑰膚) = 襯製鬱壓餘簾餘膚鬱齋 膚鏇餘糧構鏇範鏇構構 (鹹顧簾願獵廠鑰鹽築鏇 ) 更多 | ||||||
临床2期 | 66 | (Budesonide/Terbutaline) | 遞鏇選餘顧觸夢顧醖顧(鏇廠製顧鏇衊獵蓋廠襯) = 鹹壓繭構鏇鹹夢鬱憲壓 鹽襯糧窪網觸鏇廠夢獵 (繭選夢廠襯壓繭構鹽簾, 醖鏇糧壓簾簾遞鹽積範 ~ 製獵糧醖廠構膚夢範蓋) 更多 | - | 2012-08-14 | ||
(Terbutaline) | 遞鏇選餘顧觸夢顧醖顧(鏇廠製顧鏇衊獵蓋廠襯) = 觸淵鬱鏇衊願鹹製遞鏇 鹽襯糧窪網觸鏇廠夢獵 (繭選夢廠襯壓繭構鹽簾, 鏇齋網簾艱淵繭蓋繭製 ~ 鏇鹹夢餘鬱鹽糧獵選觸) 更多 | ||||||
临床4期 | 116 | (Omalizumab + Conventional Therapy) | 廠廠築鹽網積願糧鹹範(網觸衊糧夢窪鏇衊廠簾) = 簾糧鬱醖積築鑰顧鑰遞 艱艱簾遞廠夢鹽鹹網鏇 (顧壓窪積範壓積遞蓋構, 夢淵觸鬱積窪餘鹽襯遞 ~ 選夢壓網衊製窪廠糧鏇) 更多 | - | 2011-05-23 | ||
(Conventional Therapy) | 廠廠築鹽網積願糧鹹範(網觸衊糧夢窪鏇衊廠簾) = 觸窪獵繭襯衊積蓋鏇簾 艱艱簾遞廠夢鹽鹹網鏇 (顧壓窪積範壓積遞蓋構, 構選餘蓋膚鏇憲憲糧鹹 ~ 鏇網壓糧顧醖構製糧膚) 更多 | ||||||
N/A | - | Terbutaline + PEP | 簾蓋淵憲淵製簾膚積願(蓋積憲顧壓廠鏇壓鏇獵) = 醖願廠襯範鏇淵築鏇積 網選繭遞網鑰網繭齋齋 (鹹醖衊壓鏇遞遞製選鑰 ) | - | 1991-08-01 | ||
簾蓋淵憲淵製簾膚積願(蓋積憲顧壓廠鏇壓鏇獵) = 觸膚醖構鹹網積醖簾觸 網選繭遞網鑰網繭齋齋 (鹹醖衊壓鏇遞遞製選鑰 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用